NCT04537689View on ClinicalTrials.gov

Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis

PHASE4RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 10, 2020

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Plaque Psoriasis
Interventions
BIOLOGICAL

Ixekizumab

Ixekizumab for 6 months, given 160mg at weeks 0, followed by 80mg at 2, 4, 6, 8, 10 and 12, then 4 weekly till 6 months. Given subcutaneously.

DRUG

Methotrexate

Oral tablet up to 15mg per week

DRUG

Cyclosporin A

Oral capsule up to 200mg per day

DRUG

Acitretin

Oral capsule up to 25mg per day

Trial Locations (1)

169608

RECRUITING

Singapore General Hospital, Outram Park

All Listed Sponsors
collaborator

Translational Immunology Institute

UNKNOWN

lead

Singapore General Hospital

OTHER